NO20011757D0 - Reversering av viral-indusert systemisk sjokk og åndenöd ved blokkering av lymfotoksin-<beta>-veien - Google Patents

Reversering av viral-indusert systemisk sjokk og åndenöd ved blokkering av lymfotoksin-<beta>-veien

Info

Publication number
NO20011757D0
NO20011757D0 NO20011757A NO20011757A NO20011757D0 NO 20011757 D0 NO20011757 D0 NO 20011757D0 NO 20011757 A NO20011757 A NO 20011757A NO 20011757 A NO20011757 A NO 20011757A NO 20011757 D0 NO20011757 D0 NO 20011757D0
Authority
NO
Norway
Prior art keywords
viral
blocking
lymphotoxin
shortness
breath
Prior art date
Application number
NO20011757A
Other languages
English (en)
Other versions
NO326905B1 (no
NO20011757L (no
Inventor
Jeffrey Browning
Maryann Puglielli
Rafi Ahmed
Original Assignee
Biogen Inc
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ Emory filed Critical Biogen Inc
Publication of NO20011757D0 publication Critical patent/NO20011757D0/no
Publication of NO20011757L publication Critical patent/NO20011757L/no
Publication of NO326905B1 publication Critical patent/NO326905B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20011757A 1998-10-09 2001-04-06 Reversering av viral-indusert systemisk sjokk og andenod ved blokkering av lymfotoksin-<beta>-veien NO326905B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09
PCT/US1999/023477 WO2000021558A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Publications (3)

Publication Number Publication Date
NO20011757D0 true NO20011757D0 (no) 2001-04-06
NO20011757L NO20011757L (no) 2001-06-08
NO326905B1 NO326905B1 (no) 2009-03-16

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011757A NO326905B1 (no) 1998-10-09 2001-04-06 Reversering av viral-indusert systemisk sjokk og andenod ved blokkering av lymfotoksin-<beta>-veien

Country Status (27)

Country Link
US (3) US20020001585A1 (no)
EP (1) EP1119370B1 (no)
JP (2) JP4713738B2 (no)
KR (1) KR100888832B1 (no)
CN (1) CN1200733C (no)
AT (1) ATE329618T1 (no)
AU (1) AU777492C (no)
BR (1) BR9915025A (no)
CA (1) CA2344049C (no)
CY (1) CY1105059T1 (no)
CZ (1) CZ20011272A3 (no)
DE (1) DE69931944T2 (no)
DK (1) DK1119370T3 (no)
EA (1) EA006703B1 (no)
EE (1) EE04661B1 (no)
ES (1) ES2267294T3 (no)
HU (1) HUP0103773A3 (no)
IL (2) IL142284A0 (no)
IS (1) IS2514B (no)
NO (1) NO326905B1 (no)
NZ (1) NZ510560A (no)
PL (1) PL195264B1 (no)
PT (1) PT1119370E (no)
SG (1) SG121778A1 (no)
SK (1) SK4662001A3 (no)
TR (1) TR200100974T2 (no)
WO (1) WO2000021558A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) * 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
ATE483807T1 (de) * 2000-04-12 2010-10-15 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1756162A1 (en) * 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2009004134A (es) 2006-10-20 2009-08-12 Biogen Idec Inc Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
JP2010539243A (ja) * 2007-09-18 2010-12-16 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
EP0536299B1 (en) * 1990-06-27 2001-06-06 Biogen, Inc. Surface complexed lymphotoxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH08507201A (ja) 1992-12-04 1996-08-06 バイオジェン，インコーポレイテッド リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
PL185364B1 (pl) 1995-01-26 2003-04-30 Biogen Kompozycje farmaceutyczne do leczenia albo zmniejszenia zaawansowania, ciężkości albo skutków powstawania nowotworu
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
PT954333E (pt) * 1996-10-25 2006-10-31 Biogen Idec Inc Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) * 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies

Also Published As

Publication number Publication date
IS2514B (is) 2009-06-15
ATE329618T1 (de) 2006-07-15
AU777492C (en) 2005-05-26
DK1119370T3 (da) 2006-10-02
US20090087403A1 (en) 2009-04-02
JP4713738B2 (ja) 2011-06-29
DE69931944T2 (de) 2007-02-08
IL142284A (en) 2009-11-18
DE69931944D1 (de) 2006-07-27
EA200100430A1 (ru) 2001-10-22
IL142284A0 (en) 2002-03-10
EP1119370A1 (en) 2001-08-01
KR20010080073A (ko) 2001-08-22
AU6296499A (en) 2000-05-01
HUP0103773A2 (hu) 2002-01-28
JP2002527403A (ja) 2002-08-27
SG121778A1 (en) 2006-05-26
US7452530B2 (en) 2008-11-18
US20040198635A1 (en) 2004-10-07
CA2344049C (en) 2009-12-15
EA006703B1 (ru) 2006-02-24
WO2000021558A1 (en) 2000-04-20
CN1200733C (zh) 2005-05-11
KR100888832B1 (ko) 2009-03-17
EE200100211A (et) 2002-08-15
TR200100974T2 (tr) 2001-11-21
BR9915025A (pt) 2001-08-14
NZ510560A (en) 2003-09-26
CA2344049A1 (en) 2000-04-20
JP2010155852A (ja) 2010-07-15
AU777492B2 (en) 2004-10-21
CZ20011272A3 (cs) 2001-09-12
US20020001585A1 (en) 2002-01-03
PL347177A1 (en) 2002-03-25
EP1119370B1 (en) 2006-06-14
CY1105059T1 (el) 2010-03-03
WO2000021558A9 (en) 2001-05-25
NO326905B1 (no) 2009-03-16
PL195264B1 (pl) 2007-08-31
EE04661B1 (et) 2006-08-15
CN1323223A (zh) 2001-11-21
NO20011757L (no) 2001-06-08
HUP0103773A3 (en) 2003-10-28
PT1119370E (pt) 2006-09-29
SK4662001A3 (en) 2001-11-06
ES2267294T3 (es) 2007-03-01
IS5882A (is) 2001-03-09

Similar Documents

Publication Publication Date Title
NO20011757D0 (no) Reversering av viral-indusert systemisk sjokk og åndenöd ved blokkering av lymfotoksin-&lt;beta&gt;-veien
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
DK1041990T3 (da) Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin
YU12097A (en) 6-phenilpyridyl-2-amine derivatives
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
DE69905368T2 (de) Oxydiertes thymosin beta 4
DE69811062T2 (de) Polyaromatische antivirale zusammensetzungen
PT1073416E (pt) Utilização de óxido nítrico inalado como agente anti-inflamatório
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DE60025848D1 (en) Pyrimidin-derivate als selective inhibitoren von cox-2
NO933524D0 (no) Krystallisk tiagabinhydrokloridmonohydrat samt fremstilling og anvendelse derav
NO983672L (no) Prevensjonssystem med antibakteriell effekt og/eller antiviruseffekt
DK0509120T3 (da) Topisk anvendelse af glycosaminoglycaner til forebyggelse og behandling af sygdomme, der påvirker det cervikale vaginale område
BR9612245A (pt) Inibidor de óxido nitrico (no) sintase para tratamento ou prevenção de diabetes tipo ii
Fujita Experimental studies of stimulated brillouin scattering from KrF laser-produced plasma
ZA833161B (en) N2-(substituted)carboxymethyl-n6-(substituded)-lysyl and a-(e-aminoalkyl)glycyl amino acid antihypertensive agents
ZA989550B (en) Use of inhaled no as anti-inflammatory agent.
KR950011622U (ko) 급냉응고용 석영관의 구조
TH27468A (th) ส่วนประกอบและวิธีสำหรับการบำบัดรักษาสภาพซึ่งอาศัยสื่อกลางเซลล์แมสท์(Mast)
KR950010435U (ko) 모니터의 프론트마스크 구조

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees